Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Class A Ordinary Shares, par value $0.0001 per share
-
Shares outstanding
-
63.5M
-
Number of holders
-
32
-
Total 13F shares, excl. options
-
37.7M
-
Shares change
-
+563K
-
Total reported value, excl. options
-
$396M
-
Value change
-
+$8.23M
-
Number of buys
-
17
-
Number of sells
-
-11
-
Price
-
$10.50
Significant Holders of MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) as of Q4 2022
36 filings reported holding MLTX - MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share as of Q4 2022.
MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) has 32 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 37.7M shares
of 63.5M outstanding shares and own 59.45% of the company stock.
Largest 10 shareholders include BVF INC/IL (21.8M shares), Cormorant Asset Management, LP (6.07M shares), CITADEL ADVISORS LLC (2.89M shares), TCG Crossover Management, LLC (1M shares), Polar Capital Holdings Plc (876K shares), PRICE T ROWE ASSOCIATES INC /MD/ (823K shares), BlackRock Inc. (742K shares), GREAT POINT PARTNERS LLC (643K shares), RTW INVESTMENTS, LP (500K shares), and AXA S.A. (405K shares).
This table shows the top 32 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.